Bellicum Pharmaceuticals Announces Patent Issued on Methods for Inducing Selective Apoptosis for its Lead Product Candidate BPX-501
“This important patent extends the proprietary rights of our lead cell
therapy product candidate, BPX-501, until at least 2031,” commented
The invention is for a method of cell therapy where cells are first modified to express an inducible caspase 9 protein. The protein, when triggered with the small molecule compound rimiducid (AP1903), induces apoptosis and rapid cell death. The cells can be selectively eliminated when a patient experiences dangerous and life threatening toxicities, such as Graft versus Host Disease. Baylor was issued U.S. patent number 9,089,520.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR-T and TCR cell therapy, and dendritic cell vaccines. More information can be found at www.bellicum.com.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing of our clinical trials and of our research and development activities and our expectations regarding our other programs. Various factors may cause differences between Bellicum’s expectations and actual results as discussed in greater detail in Bellicum’s filings with the Securities and Exchange Commission, including without limitation our annual report on Form 10-K for the year ended December 31, 2014. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.